Supernus Pharmaceuticals Inc.

About Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals is an award-winning biopharmaceutical company with over 30 years of experience in developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Products & Services

CNS Treatments:Novel products designed to provide important health benefits to patients living with central nervous system (CNS) diseases.

Qelbree™:A recently approved treatment for CNS conditions, with prescribing information and medication guides available.

Qelbree

Specialties

Central Nervous System (CNS) Treatments Research and Development Product Commercialization Central nervous system (CNS) diseases Central Nervous System (CNS) diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2023-02-14 FD: 2023-02-14	1 investors

Debt Latest

2023-02-14

$150.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jack A. Khattar

PRESIDENT AND CHIEF EXECUTIVE OFFICER, DIRECTOR

T

Timothy C. Dec

SENIOR VICE PRESIDENT CHIEF FINANCIAL OFFICER

K

Kevin T. Anderson

COMPLIANCE OFFICER

P

Padmanabh P. Bhatt

SENIOR VICE PRESIDENT CHIEF SCIENTIFIC OFFICER INTELLECTUAL PROPERTY

J

Jeff Bozick

SENIOR VICE PRESIDENT SUPPLY CHAIN

R

Roman Bradel

VICE PRESIDENT REGULATORY AFFAIRS

View 13 more team members with Pro

Unlock Full Team Directory

Recent News